Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 183

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 183
---
 | - |     |                  | - |     |            | 14,671 |     |                 |    - |   |     |             | (9,429  | ) |     |        |  5,277 |   |
| Exercise of options                            |     |               |  2,800,000 |     |               |  3 |     |                  | - |     |                  | - |     |            |      - |     |                 |    - |   |     |             | -       |   |     |        |      3 |   |
| Net loss and comprehensive loss for the period |     |               |          - |     |               |  - |     |                  | - |     |                  | - |     |            |      - |     |                 |    - |   |     |             | (2,084  | ) |     |        | (2,084 | ) |
| Issuance of business combination shares        |     |               | 23,171,642 |     |               | 23 |     |                  | - |     |                  | - |     |            | 14,284 |     |                 |  914 |   |     |             | -       |   |     |        | 15,221 |   |
| Stock based compensation                       |     |               |          - |     |               |  - |     |                  | - |     |                  | - |     |            |  1,433 |     |                 | (144 | ) |     |             | -       |   |     |        |  1,289 |   |
| Balance at December 31, 2024                   |     |               | 60,729,100 |     |               | 61 |     |                  | - |     |                  | - |     |            | 30,388 |     |                 |  770 |   |     |             | (11,513 | ) |     |        | 19,706 |   |

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-6</div>

REVIUM RX.

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

|                                                                             |     | Successor      
 For the period 
 commencing     
 July 24        
 through        
 December 31,   
 2024           |